Notice: This company has been marked as potentially delisted and may not be actively trading. Cesca Therapeutics (KOOL) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendTrends KOOL vs. THMO, KEQU, CRDL, RGLS, XGN, DERM, BHST, ANRO, IMUX, and SKYEShould you be buying Cesca Therapeutics stock or one of its competitors? The main competitors of Cesca Therapeutics include ThermoGenesis (THMO), Kewaunee Scientific (KEQU), Cardiol Therapeutics (CRDL), Regulus Therapeutics (RGLS), Exagen (XGN), Journey Medical (DERM), BioHarvest Sciences (BHST), Alto Neuroscience (ANRO), Immunic (IMUX), and Skye Bioscience (SKYE). Cesca Therapeutics vs. ThermoGenesis Kewaunee Scientific Cardiol Therapeutics Regulus Therapeutics Exagen Journey Medical BioHarvest Sciences Alto Neuroscience Immunic Skye Bioscience ThermoGenesis (NASDAQ:THMO) and Cesca Therapeutics (NASDAQ:KOOL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, community ranking, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Which has preferable earnings & valuation, THMO or KOOL? ThermoGenesis has higher earnings, but lower revenue than Cesca Therapeutics. Cesca Therapeutics is trading at a lower price-to-earnings ratio than ThermoGenesis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioThermoGenesis$9.61M0.00-$17.98M-$5.140.00Cesca Therapeutics$9.67M2.77-$39.72M-$3.60-3.08 Does the media refer more to THMO or KOOL? In the previous week, ThermoGenesis' average media sentiment score of 0.00 equaled Cesca Therapeutics'average media sentiment score. Company Overall Sentiment ThermoGenesis Neutral Cesca Therapeutics Neutral Do insiders & institutionals believe in THMO or KOOL? 5.8% of ThermoGenesis shares are held by institutional investors. Comparatively, 3.1% of Cesca Therapeutics shares are held by institutional investors. 78.0% of ThermoGenesis shares are held by company insiders. Comparatively, 68.9% of Cesca Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is THMO or KOOL more profitable? Cesca Therapeutics has a net margin of -98.84% compared to ThermoGenesis' net margin of -153.43%. Cesca Therapeutics' return on equity of -77.30% beat ThermoGenesis' return on equity.Company Net Margins Return on Equity Return on Assets ThermoGenesis-153.43% -4,838.39% -107.53% Cesca Therapeutics -98.84%-77.30%-37.75% Does the MarketBeat Community believe in THMO or KOOL? Cesca Therapeutics received 241 more outperform votes than ThermoGenesis when rated by MarketBeat users. Likewise, 70.45% of users gave Cesca Therapeutics an outperform vote while only 60.47% of users gave ThermoGenesis an outperform vote. CompanyUnderperformOutperformThermoGenesisOutperform Votes2660.47% Underperform Votes1739.53% Cesca TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% Which has more risk and volatility, THMO or KOOL? ThermoGenesis has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500. Comparatively, Cesca Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. SummaryCesca Therapeutics beats ThermoGenesis on 8 of the 13 factors compared between the two stocks. Ad MyBankTrackerYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.View the best savings account rates here Get Cesca Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KOOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOOL vs. The Competition Export to ExcelMetricCesca TherapeuticsLaboratory Apparatus & Furniture IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.82M$77.35M$5.14B$9.08BDividend Yield0.50%N/A5.09%4.23%P/E Ratio-3.088.5490.1317.19Price / Sales2.770.391,116.25117.05Price / CashN/A33.6243.1037.85Price / Book3.573.964.784.78Net Income-$39.72M$385,000.00$120.31M$225.60M Cesca Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KOOLCesca TherapeuticsN/A$11.10+1.0%N/A+1,864.6%$26.82M$9.67M-3.0853THMOThermoGenesisN/A$0.00flatN/A-99.9%$4,000.00$9.61M0.0025KEQUKewaunee Scientific2.2555 of 5 stars$53.60+0.4%N/A+118.0%$153.94M$199.64M8.461,006Analyst UpgradeInsider TradeGap DownCRDLCardiol Therapeutics2.2523 of 5 stars$1.33-0.4%$8.75+560.4%+44.7%$108.26M$60,000.00-3.4120Analyst ForecastAnalyst RevisionNews CoverageGap DownRGLSRegulus Therapeutics2.7312 of 5 stars$1.65+4.4%$10.80+554.5%+28.2%$108.08MN/A-1.4830News CoverageXGNExagen4.6639 of 5 stars$6.00+3.8%$7.00+16.7%+197.7%$105.84M$52.55M-6.14220High Trading VolumeDERMJourney Medical2.5422 of 5 stars$5.04-1.0%$9.38+86.0%N/A$105.29M$79.18M-5.4190BHSTBioHarvest SciencesN/A$6.32+2.8%$14.00+121.5%N/A$103.81M$22.43M-4.92N/AAnalyst ForecastANROAlto Neuroscience3.2674 of 5 stars$3.84+0.3%$20.00+420.8%N/A$103.57M$210,000.000.00N/AGap UpIMUXImmunic2.7773 of 5 stars$1.14+0.9%$11.80+935.0%-28.6%$102.70MN/A-0.9270Positive NewsSKYESkye Bioscience2.186 of 5 stars$3.38+0.9%$18.67+452.3%-11.8%$102.54MN/A0.0011News CoveragePositive NewsGap Down Related Companies and Tools Related Companies THMO Alternatives KEQU Alternatives CRDL Alternatives RGLS Alternatives XGN Alternatives DERM Alternatives BHST Alternatives ANRO Alternatives IMUX Alternatives SKYE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KOOL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cesca Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
